Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Net Cash Flow (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Net Cash Flow for 15 consecutive years, with -$3.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow fell 792.37% to -$3.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$7.2 million, a 28.27% decrease, with the full-year FY2024 number at -$2.6 million, down 10.51% from a year prior.
  • Net Cash Flow was -$3.2 million for Q3 2025 at NovaBay Pharmaceuticals, roughly flat from -$3.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $2.2 million in Q4 2024 to a low of -$3.2 million in Q2 2025.
  • A 5-year average of -$1.1 million and a median of -$1.3 million in 2021 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: crashed 1754.55% in 2023, then surged 393.61% in 2024.
  • NovaBay Pharmaceuticals' Net Cash Flow stood at -$1.5 million in 2021, then surged by 219.82% to $1.8 million in 2022, then plummeted by 141.13% to -$751000.0 in 2023, then soared by 393.61% to $2.2 million in 2024, then crashed by 243.27% to -$3.2 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Net Cash Flow are -$3.2 million (Q3 2025), -$3.2 million (Q2 2025), and -$3.0 million (Q1 2025).